Drug firm Cipla Friday said the US health regulator conducted a post-approval inspection at its Indore facility, and it ended with zero observations.
"We would like to inform you that the USFDA (US Food and Drug Administration) conducted a post-approval inspection at our Indore facility from 13th May to 17th May, 2019. The inspection ended with zero observations," the company said in a BSE filing.
Shares of Cipla closed at Rs 543.95 apiece on the BSE, down 1.2 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
